Heron Therapeutics, Inc. (HRTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heron Therapeutics, Inc. on June 25, 2026. The filing addresses a regulatory notice received from The Nasdaq Stock Market regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to Nasdaq listing requirements.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On June 25, 2026, the Company received notice that its common stock closing bid price was below the minimum $1.00 per share requirement for 30 consecutive trading days (May 12, 2026, to June 24, 2026).
- Compliance Period: The Company has been granted an initial 180-calendar-day period, ending December 22, 2026, to regain compliance.
- Trading Status: The notice has no immediate impact on trading; shares will continue to trade on The Nasdaq Capital Market under the symbol "HRTX" subject to continued compliance.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing share price and explore available options to regain compliance. To qualify for a second 180-day compliance period if the initial period is unsuccessful, the Company must meet the market value of publicly held shares requirement and all other initial listing standards, potentially effecting a reverse stock split. There is no assurance that the Company will regain compliance or avoid delisting. The filing includes standard forward-looking statements regarding the uncertainty of meeting bid price requirements and maintaining listing status.
Investor Verification Checklist
- Verify the current closing bid price of HRTX to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial health, cash runway, and existing debt obligations.
- Monitor for announcements regarding a potential reverse stock split or other capital structure changes intended to cure the deficiency.
- Check for any subsequent communications from Nasdaq regarding the Company's compliance status or potential delisting proceedings.